For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

A giant functional atlas of immune cells in a Chinese cohort reveals crucial differences with European and Japanese data sets ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell-known as helper T cells-from stem cells in a ...

H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune DiseaseInterim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with ...

Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

Cell division is an essential process for all life on earth, yet the exact mechanisms by which cells divide during early ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

For the first time, scientists have answered a longstanding question in cell biology about a partnership of proteins called ...